CONTACT:Investor Relations: firstname.lastname@example.orgWill O'ConnorStern Investor RelationsWill@sternir.com 212-362-1200 Media:Becky VonsiatskyW2O Groupbvonsiatsky@w2ogroup.com413-478-2003
DURHAM, N.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering and developing medicines that improve outcomes for immunocompromised patients, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the 35 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 8:30 a.m. PT (11:30 a.m. ET) at the Westin Saint Francis Hotel in San Francisco, CA. A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at http://ir.chimerix.com/events.cfm, where it will be archived for approximately 90 days. About Chimerix Chimerix is a biopharmaceutical company dedicated to discovering and developing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage compounds. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.